1,450 views
A few days ago, the European Medicines Agency preliminarily authorized the use of dupilumab, a biological drug against interleukin 4 and 13, for the treatment of patients with uncontrolled chronic obstructive pulmonary disease (COPD). In particular, this approval will concern patients with COPD who have a history of two or more exacerbations in the previous year, despite maximizing inhaled therapy with triple therapy consisting of two bronchodilators and inhaled steroid, and a level of eosinophils in the peripheral blood that is equal to or greater than 300 cells per microliter. The important aspect is that the data from these two randomized, placebo-controlled twins (BOREAS and NOTUS) with International Breath have demonstrated the efficacy of dupilumab added to inhaled therapy and maximized and reducing the rate of exacerbations by improving respiratory function and improving the quality of life of these patients. We talked about it with Professor Pierachille Santus, professor of respiratory diseases at the University of Milan.